Fig. 3

Fig. 3 New Valve Cells Differentiate from Endothelial Cells and Kidney Marrow-Derived Cells (A and A?) EdU detection and kdrl:GFP expression in 48 hpab valves (arrowheads point to double-positive cells; n = 4). (B) Uninjured valve showing absence of fli1a:H2B-GFP expression in VICs (n = 4). (C and D) Characterization (C and C?; n = 4) and quantification of the percentage (D) of EdU+ cells positive for fli1a:H2B-GFP expression. Boxed areas shown in (A?) and (C?). (E) Co-localization of kdrl reporter with Fli1 antibody (arrowheads; n = 4). Boxed areas shown in E? and (E?). (F?G??) Cre/lox lineage tracing experiments show a few endothelial-derived nfatc1+ cells (arrowheads) in uninjured valves (F and F?; n = 6) and contribution of endothelial cells to nfatc1+ VICs (arrowheads) at 14 dpab (G?G??; n = 9). Boxed areas shown in (F?) and (G??G??). Yellow and pink dashed lines delineate the old and new valve leaflets, respectively. (H?I?) WKM-derived cells in uninjured valves (H and H?; n = 3) and positive for EdU (I?I?) at 48 hpab. (J?K?) Quantification (J) and localization (K?K?) of WKM-derived cells negative for the immune cell marker L-Plastin. Boxed areas shown in (H?), (I?), (I?), (K?), and (K?). (L?L??) Contribution of circulating WKM-derived cells to new nfatc1+ cells (arrowheads) at 14 dpab (n = 4). Boxed areas shown in (L??L??). A, atrium; V, ventricle. Scale bars: (A), (B), (C), (E), (F), (G), (H), (I), (K), and (L) 100 ?m; (A?), (C?), (E? and E?), (F?), (G??G??), (H?), (I??I?), (K? and K?), and (L??L??) 20 ?m.